HIV-1 testing during labor
This article was originally published in The Gray Sheet
Executive Summary
Widespread rapid HIV testing during labor would be cost-saving to the medical system, according to authors of the CDC-funded, 91,707-patient, Mother-Infant Rapid Intervention At Delivery (MIRIAD) trial. "Our study demonstrates that, in general, results are timely and that antiretroviral prophylaxis can be provided promptly to HIV-infected women and their infants," Marc Bulterys, MD/PhD, CDC, et al., explain in the July 14 issue of JAMA. Rapid HIV-1 tests administered during labor were 100% sensitive and 99.9% specific with a positive predictive value of 90%. Perinatal HIV testing would be especially valuable in the developing world, where "pregnant women with unknown HIV status are often seen by clinicians for the first time during labor," the authors note...
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.